Amyris Inc (NASDAQ:AMRS) Posts Another Remarkable Quarter


Amyris Inc (NASDAQ:AMRS) posted preliminary unaudited financial report for the fourth quarter closed December 31, 2017. GAAP revenue for Q4 2017 came at $80.6 million versus $22.2 million for Q4 2016. The firm recognized license and royalty revenues of approximately $57.3 million from the value share and multi-element license deal with DSM. Hence, license and royalty revenues led to $57.7 million and recorded an increase of $0.3 million from Q4 2016. Product sales came at $13.4 million for Q4 2017 versus $11.2 million for Q4 2016.

The buzz

John Melo, the CEO and President of Amyris, expressed that they have closed another record year and an extremely robust fourth quarter. They have surpassed their major targets for 2017 and have begun 2018 with sustained strong growth in operating performance and revenues. They are done with the transformation of their firm into one of the major international firms emphasized on making their planet healthier.

The company has organized around three major markets, Performance Health and Wellness, Pure Flavor and Fragrance Ingredients, and Clean Skin-Care. Each of these segments is offering strong, profitable growth supported by the most benefitted technology in the segment. They are making better for humanity and their planet with No Compromise® offerings. Melo expressed that they are extremely delighted with their performance and anticipate another extremely robust year offering continued market disruption with their associates.

Other key developments and operating highlights during Q4 2017 and more recently comprised expanded strategic association with DSM via the sale of Amyris Brasil Ltda. and set long-term manufacturing association for Amyris’s high-volume offerings; successfully introduced Biossance into SEPHORA Canada outlets, with SEPHORA U.S. sales during 2071 overall contributing to over 650% jump in aggregate 2017 Biossance retail sales in 2016. Amyris launched Neossance® Squalane USP via their Aprinnova joint venture introducing new segments among FDA regulated offerings such as dermal and topical applications.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.